Tuesday, 18 Jun 2019

You are here

RheumNow Week in Review – 22 April 2016

Highlights from this week on RheumNow.com

  1. Systematic review by Felson et al shows that MTX use in current RA clinical trials is suboptimal, most using 15mg, the highest dose was 20mg/wk and only one trial with parenteral MTX.  https://t.co/1DYHxLK2DJ
  2. There's a despirate need for effective DMARD or biologic therapy for patients with with erosive osteoarthritis! GSK announced the launch of its Phase 2 trial of GM-CSF MAb in patients with inflammatory hand OA. https://t.co/cXNdTDufR7
  3. Celltrion chief executive said that Inflectra is expected to be priced ~20-30% lower than Remicade when released in the US. https://t.co/ceCHuYubzK
  4. Perioperative MTX use does not cause increased postoperative infectious complications or sepsis in IBD patients having abdominal surgery. https://t.co/ApgCyEhpeG
  5. A New Look at Old Pictures.  Dr. David Pisetsky blogs on the appropriate or misleading use of picture to educate. 
  6. Do's and Don'ts of Vaccination: a (Very) Brief Guide for Rheumatologists by Dr. Kevin Winthrop.  
  7. Vaccine Success is Limited in Rheumatoid Arthritis.  
  8. α Defensin Control of Inflammation.  The protective effects of defensins and their therapeutic potential is proposed.  
  9. BeST Trial and 10-Year Outcomes of Four Treatment Strategies
  10. Osteoporotic Fractures at Higher Risk for Subsequent Fractures  

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2019- Day 4 Report

Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.

Below are the top “LB” presentations from EULAR this year:

Understanding Non-arthritic Rheumatic iRAEs

A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA